OSE Immunotherapeutics SA (OSE.PA)
EUR 7.17
(-1.38%)
EUR 7.17
(-1.38%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -22.98 Million EUR | -34.6% |
| 2022 | -24.03 Million EUR | -9.39% |
| 2021 | -21.97 Million EUR | 11.17% |
| 2020 | -24.73 Million EUR | -388.76% |
| 2019 | -5.06 Million EUR | -204.42% |
| 2018 | 4.84 Million EUR | 138.39% |
| 2017 | -12.62 Million EUR | -2126.63% |
| 2016 | -567 Thousand EUR | 89.54% |
| 2015 | -5.42 Million EUR | -92.54% |
| 2014 | -2.81 Million EUR | -1026.0% |
| 2013 | -250 Thousand EUR | 82.7% |
| 2012 | -1.44 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 46.12 Million EUR | 0.0% |
| 2023 Q2 | -19.2 Million EUR | 0.0% |
| 2023 Q4 | -9.48 Million EUR | 0.0% |
| 2023 FY | -32.35 Million EUR | -34.6% |
| 2022 Q2 | -6.76 Million EUR | 0.0% |
| 2022 Q4 | -17.25 Million EUR | 0.0% |
| 2022 FY | -24.03 Million EUR | -9.39% |
| 2021 FY | -21.97 Million EUR | 11.17% |
| 2021 Q4 | -7.07 Million EUR | 0.0% |
| 2021 Q2 | -14.89 Million EUR | 0.0% |
| 2020 Q4 | -11.91 Million EUR | 0.0% |
| 2020 FY | -24.73 Million EUR | -388.76% |
| 2020 Q2 | -7.08 Million EUR | 0.0% |
| 2019 Q4 | -6.49 Million EUR | 0.0% |
| 2019 Q2 | 1.43 Million EUR | 0.0% |
| 2019 FY | -5.06 Million EUR | -204.42% |
| 2018 FY | 4.84 Million EUR | 138.39% |
| 2018 Q2 | 10.35 Million EUR | 0.0% |
| 2018 Q4 | -5.51 Million EUR | 0.0% |
| 2017 FY | -12.62 Million EUR | -2126.63% |
| 2017 Q4 | -5.28 Million EUR | 0.0% |
| 2017 Q2 | -7.33 Million EUR | 0.0% |
| 2016 FY | -567 Thousand EUR | 89.54% |
| 2016 Q4 | -4.79 Million EUR | 0.0% |
| 2016 Q2 | 4.22 Million EUR | 0.0% |
| 2015 FY | -5.42 Million EUR | -92.54% |
| 2015 Q4 | -2.62 Million EUR | 0.0% |
| 2015 Q2 | -2.79 Million EUR | 0.0% |
| 2014 FY | -2.81 Million EUR | -1026.0% |
| 2014 Q4 | -2.16 Million EUR | 0.0% |
| 2014 Q2 | -654 Thousand EUR | 0.0% |
| 2013 Q1 | -61 Thousand EUR | 0.0% |
| 2013 Q2 | -122 Thousand EUR | -100.0% |
| 2013 Q3 | -64 Thousand EUR | 47.54% |
| 2013 FY | -250 Thousand EUR | 82.7% |
| 2013 Q4 | -128 Thousand EUR | -100.0% |
| 2012 FY | -1.44 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -573.681% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 81.954% |
| Adocia SA | -17.62 Million EUR | -30.439% |
| Aelis Farma SA | -6.46 Million EUR | -255.765% |
| Biophytis S.A. | -14.33 Million EUR | -60.371% |
| Advicenne S.A. | -6.45 Million EUR | -255.986% |
| genOway Société anonyme | 2.06 Million EUR | 1212.964% |
| IntegraGen SA | -183.77 Thousand EUR | -12408.026% |
| Medesis Pharma S.A. | -4.22 Million EUR | -443.489% |
| Neovacs S.A. | -6.9 Million EUR | -232.766% |
| NFL Biosciences SA | -4.43 Million EUR | -418.822% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -2853.599% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -632.679% |
| Sensorion SA | -22.31 Million EUR | -3.027% |
| Theranexus Société Anonyme | -7.64 Million EUR | -200.719% |
| TME Pharma N.V. | -5.62 Million EUR | -308.713% |
| Valbiotis SA | -7.16 Million EUR | -221.034% |
| TheraVet SA | -2.17 Million EUR | -956.775% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -13.299% |
| argenx SE | -417.15 Million EUR | 94.49% |
| BioSenic S.A. | -7.04 Million EUR | -226.506% |
| Celyad Oncology SA | -8.45 Million EUR | -171.799% |
| DBV Technologies S.A. | -85.24 Million EUR | 73.036% |
| Galapagos NV | -88.26 Million EUR | 73.957% |
| Genfit S.A. | -26.58 Million EUR | 13.521% |
| GeNeuro SA | -14.35 Million EUR | -60.1% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -43.725% |
| Innate Pharma S.A. | -12.66 Million EUR | -81.435% |
| Inventiva S.A. | -102.7 Million EUR | 77.62% |
| MaaT Pharma SA | -19.94 Million EUR | -15.258% |
| MedinCell S.A. | -20.97 Million EUR | -9.577% |
| Nanobiotix S.A. | -26.77 Million EUR | 14.164% |
| Onward Medical N.V. | -35.46 Million EUR | 35.183% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -405.276% |
| Oxurion NV | -12.11 Million EUR | -89.81% |
| Pharming Group N.V. | -4.87 Million EUR | -371.069% |
| Poxel S.A. | -28.76 Million EUR | 20.088% |
| GenSight Biologics S.A. | -29.69 Million EUR | 22.596% |
| Transgene SA | -30.01 Million EUR | 23.411% |
| Financière de Tubize SA | -2.14 Million EUR | -972.121% |
| UCB SA | 604 Million EUR | 103.806% |
| Valneva SE | -82.08 Million EUR | 71.998% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 20.29% |